TY - JOUR
T1 - Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region
AU - Anadkat, Milan J.
AU - Lacouture, Mario
AU - Friedman, Adam
AU - Horne, Zachary D.
AU - Jung, Jae
AU - Kaffenberger, Benjamin
AU - Kalmadi, Sujith
AU - Ovington, Liza
AU - Kotecha, Rupesh
AU - Abdullah, Huda Ismail
AU - Grosso, Federica
N1 - Funding Information:
Medical writing support under the direction of the authors was provided by Imogen Francis, BSc, and Melissa Purves, PhD, both of Prime, Knutsford, UK.
Publisher Copyright:
Copyright © 2023 Anadkat, Lacouture, Friedman, Horne, Jung, Kaffenberger, Kalmadi, Ovington, Kotecha, Abdullah and Grosso.
PY - 2023/1/4
Y1 - 2023/1/4
N2 - Tumor Treating Fields (TTFields) are electric fields, delivered via wearable arrays placed on or near the tumor site, that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. As a first-in-class treatment, TTFields therapy is approved for use in newly diagnosed glioblastoma, recurrent glioblastoma, and pleural mesothelioma. Additionally, TTFields therapy is being investigated in non-small cell lung cancer (NSCLC), brain metastases from NSCLC, pancreatic cancer, ovarian cancer, hepatocellular carcinoma, and gastric adenocarcinoma. Because TTFields therapy is well tolerated and delivery is locoregional, there is low risk of additive systemic adverse events (AEs) when used with other cancer treatment modalities. The most common AE associated with TTFields therapy is mild-to-moderate skin events, which can be treated with topical agents and may be managed without significant treatment interruptions. Currently, there are no guidelines for oncologists regarding the management of TTFields therapy-related skin AEs in the thoracic region, applicable for patients with pleural mesothelioma or NSCLC. This publication aims to provide guidance on preventing, minimizing, and managing dermatologic AEs in the thoracic region to help improve patient quality of life and reduce treatment interruptions that may impact outcomes with TTFields therapy.
AB - Tumor Treating Fields (TTFields) are electric fields, delivered via wearable arrays placed on or near the tumor site, that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. As a first-in-class treatment, TTFields therapy is approved for use in newly diagnosed glioblastoma, recurrent glioblastoma, and pleural mesothelioma. Additionally, TTFields therapy is being investigated in non-small cell lung cancer (NSCLC), brain metastases from NSCLC, pancreatic cancer, ovarian cancer, hepatocellular carcinoma, and gastric adenocarcinoma. Because TTFields therapy is well tolerated and delivery is locoregional, there is low risk of additive systemic adverse events (AEs) when used with other cancer treatment modalities. The most common AE associated with TTFields therapy is mild-to-moderate skin events, which can be treated with topical agents and may be managed without significant treatment interruptions. Currently, there are no guidelines for oncologists regarding the management of TTFields therapy-related skin AEs in the thoracic region, applicable for patients with pleural mesothelioma or NSCLC. This publication aims to provide guidance on preventing, minimizing, and managing dermatologic AEs in the thoracic region to help improve patient quality of life and reduce treatment interruptions that may impact outcomes with TTFields therapy.
KW - TTFields
KW - Tumor Treating Fields
KW - skin adverse events
KW - skin management
KW - thoracic oncology
UR - http://www.scopus.com/inward/record.url?scp=85147019097&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.975473
DO - 10.3389/fonc.2022.975473
M3 - Review article
C2 - 36703794
AN - SCOPUS:85147019097
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 975473
ER -